Kamada (NASDAQ:KMDA) Stock Price Passes Below Two Hundred Day Moving Average - What's Next?

Key Points

• Kamada Ltd. (NASDAQ:KMDA) has fallen below its 200-day moving average of $6.99, trading at $6.82 with a total volume of 49,651 shares.
• The stock received a "buy (b-)" rating from Weiss Ratings, with three analysts suggesting a Buy and one a Hold, leading to an average price target of $13.00.
• In the last earnings report, Kamada reported an EPS of $0.13, exceeding expectations, but its revenue of $44.75 million fell significantly short of analyst estimates of $158.59 million.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $6.99 and traded as low as $6.79. Kamada shares last traded at $6.82, with a volume of 49,651 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a "buy (b-)" rating on shares of Kamada in a research report on Saturday, September 27th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $13.00.

Kamada Stock Up 0.3%

The company has a market cap of $392.22 million, a price-to-earnings ratio of 20.06, a price-to-earnings-growth ratio of 0.72 and a beta of 0.84. The firm has a 50-day simple moving average of $7.08 and a 200 day simple moving average of $6.99.

Kamada (NASDAQ:KMDA - Get Free Report) last released its quarterly earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.09 by $0.04. The company had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada had a return on equity of 7.41% and a net margin of 11.22%. Kamada has set its FY 2025 guidance at EPS. As a group, research analysts expect that Kamada Ltd. will post 0.23 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. acquired a new position in Kamada during the first quarter worth approximately $497,000. Huntleigh Advisors Inc. acquired a new position in shares of Kamada in the first quarter valued at approximately $863,000. Trexquant Investment LP acquired a new position in shares of Kamada in the first quarter valued at approximately $82,000. Jane Street Group LLC acquired a new position in shares of Kamada in the first quarter valued at approximately $582,000. Finally, Arrowstreet Capital Limited Partnership acquired a new position in shares of Kamada in the second quarter valued at approximately $472,000. Institutional investors and hedge funds own 20.38% of the company's stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.